Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · October 12, 2017

Brentuximab Vedotin Improves Outcomes in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Blood

 

Additional Info

Blood
Five-Year Results of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Blood 2017 Oct 03;[EPub Ahead of Print], B Pro, R Advani, P Brice, NL Bartlett, JD Rosenblatt, T Illidge, J Matous, R Ramchandren, M Fanale, JM Connors, K Fenton, D Huebner, JM Pinelli, DA Kennedy, A Shustov

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading